Warning: The NCBI web site requires JavaScript to function. more...
Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer.
Arteaga CL.
Breast Cancer Res. 2003;5(2):96-100. Epub 2003 Feb 3.
Related citations
Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.
McKeage K, Perry CM.
Drugs. 2002;62(1):209-43. Review.
Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
Shak S.
Semin Oncol. 1999 Aug;26(4 Suppl 12):71-7. Review.
Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/neu-overexpressing metastatic breast cancer.
Sawaki M, Ito Y, Tada K, Mizunuma N, Takahashi S, Horikoshi N, Kasumi F, Akiyama F, Sakamoto G, Imai T, Nakao A, Hatake K.
Tumori. 2004 Jan-Feb;90(1):40-3.
Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.
Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L.
Semin Oncol. 1999 Aug;26(4 Suppl 12):78-83.
Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer.
Hortobagyi GN.
Semin Oncol. 2001 Dec;28(6 Suppl 18):43-7. Review.
Antibodies as molecular target-based therapy: trastuzumab.
Tokuda Y.
Int J Clin Oncol. 2003 Aug;8(4):224-9. Review.
[Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M.
Orv Hetil. 2001 Nov 18;142(46):2563-8. Review. Hungarian.
Trastuzumab in metastatic breast cancer.
Tomao F, Miele E, Spinelli GP, Russillo M, La Ferla G, Tomao S.
Eur J Gynaecol Oncol. 2006;27(3):247-9.
Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
Goldenberg MM.
Clin Ther. 1999 Feb;21(2):309-18. Review.
[Herceptin, a monoclonal humanized antibody anti-HER2: a major therapeutic progress in breast cancers overexpressing this oncogene?].
Beuzeboc P, Scholl S, Garau XS, Vincent-Salomon A, Cremoux PD, Couturier J, Palangié T, Pouillart P.
Bull Cancer. 1999 Jun;86(6):544-9. Review. French.
Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
Emens LA.
Am J Ther. 2005 May-Jun;12(3):243-53. Review.
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
J Clin Oncol. 1996 Mar;14(3):737-44.
Gemcitabine and trastuzumab combinations for patients with metastatic breast cancer overexpressing HER2/neu.
Stein S, DeMichele A, Domchek S, Fox K.
Clin Breast Cancer. 2004 Jan;4 Suppl 3:S117-20. Review.
Her2-positive breast cancer: herceptin and beyond.
Dean-Colomb W, Esteva FJ.
Eur J Cancer. 2008 Dec;44(18):2806-12. Epub 2008 Nov 18. Review.
From HER2 to herceptin.
Mokbel K, Hassanally D.
Curr Med Res Opin. 2001;17(1):51-9. Review.
Efficacy and safety of Herceptin in women with metastatic breast cancer: results from pivotal clinical studies.
Smith IE.
Anticancer Drugs. 2001 Dec;12 Suppl 4:S3-10. Review.
Spotlight on Trastuzumab in the management of HER2-positive metastatic and early-stage breast cancer.
Plosker GL, Keam SJ.
BioDrugs. 2006;20(4):259-62. Review.
Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer.
Yeon CH, Pegram MD.
Invest New Drugs. 2005 Oct;23(5):391-409. Review.
Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP, Luftner D, Ghani F.
Breast Cancer Res. 2005;7(4):R436-43. Epub 2005 Apr 8.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on